Table 1.

Patient characteristics

Characteristic		Value
No. of patients		21
Age		median 65 (41–83)
	< 65 years	10 (47.6%)
	≥ 65 years	11 (52.4%)
Aex	male	8 (38.1%)
	female	13 (61.9%)
PS (ECOG)	0	17 (80.9%)
	1	3 (14.3%)
	3	1 (4.8%)
Pittsburgh staging	T3	10 (47.6%)
	T4	11 (52.4%)
Neurological findings before treatment	yes	8 (38.1%)
	no	13 (61.9%)
Surgery	yes	13 (61.9%)
	subtotal resection	10 (47.6%)
	complete resection	3 (14.3%)
	no	8 (38.1%)
Systemic therapy	yes	10 (47.6%)
	no	11 (52.4%)
Radiation dose (Gy)		median 66 (50.4–70.0)
	< 66	4 (19.0%)
	≥ 66	17 (81.0%)
Irradiated field	local	12 (57.1%)
	local + prophylactic	9 (42.9%)
NLR		median 2.33 (1.02–12.9)
	< 3.95	16 (76.2%)
	≥ 3.95	5 (23.8%)
CAR		median 0.04 (0.002–0.84)
	< 0.31	16 (71.4%)
	≥ 0.31	5 (28.6%)
PLR		median 153.1 (41.8–504.9)
	< 216	12 (57.1%)
	≥ 216	9 (42.9%)
AGR		median 1.32 (0.88–2.0)
	< 1.34	11 (52.4%)
	≥ 1.34	10 (47.6%)

EAC; external auditory canal, ME; middle ear, PS (ECOG); performance status (Eastern Cooperative Oncology Group), NLR; neutrophil-to-lymphocyte ratio, CAR; C-reactive protein-to-albumin ratio, PLR; platelet-to-lymphocyte ratio, AGR; albumin-to-globulin ratio.

Values are number (percentage) or median (range).